Curaleaf Holdings (CURLF) Cash from Investing Activities (2019 - 2024)
Curaleaf Holdings (CURLF) recorded quarterly Cash from Investing Activities of -$26.0 million in Q4 2024, up 6.25% quarter-over-quarter from -$27.7 million in Q3 2024, and down 26.31% on a YoY basis from -$35.3 million in Q1 2024.
Curaleaf Holdings (CURLF) Cash from Investing Activities (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$26.0 million for Q4 2024.
- In Q4 2024, Cash from Investing Activities fell 26.31% year-over-year to -$26.0 million; the TTM figure through Dec 2024 stood at -$93.8 million (down 19.24% YoY), while the FY2025 annual figure was -$69.2 million, up 26.25% from the prior year.
- Cash from Investing Activities was -$26.0 million for Q4 2024 at Curaleaf Holdings, up from -$27.7 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $26.7 billion in Q2 2023 to a low of -$26.7 billion in Q1 2023.
- Historically, Cash from Investing Activities has averaged -$31.1 million across 5 years, with a median of -$29.6 million in 2021.
- Biggest YoY gain for Cash from Investing Activities was 97.08% in 2021; the steepest drop was 88207.28% in 2021.
- A 5-year view of Cash from Investing Activities shows it stood at -$26.7 million in 2020, then slumped by 211.2% to -$83.1 million in 2021, then surged by 54.1% to -$38.1 million in 2022, then soared by 46.06% to -$20.6 million in 2023, then retreated by 26.31% to -$26.0 million in 2024.
- The last three Cash from Investing Activities figures came in at -$26.0 million (Q4 2024), -$27.7 million (Q3 2024), and $17.5 billion (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 25.99 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -15.45 Mn |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -25.99 Mn |
| Dec 31, 2024 | -25.99 Mn |
| Sep 30, 2024 | -27.72 Mn |
| Sep 30, 2024 | -27.72 Mn |
| Jun 30, 2024 | 17.51 Bn |
| Jun 30, 2024 | 17.51 Bn |
| Mar 31, 2024 | -17.55 Bn |
| Mar 31, 2024 | -17.55 Bn |
| Dec 31, 2023 | -20.58 Mn |
| Dec 31, 2023 | -20.58 Mn |
| Sep 30, 2023 | -20.17 Mn |
| Sep 30, 2023 | -20.17 Mn |
| Jun 30, 2023 | 26.69 Bn |
| Jun 30, 2023 | 26.69 Bn |
| Mar 31, 2023 | -26.73 Bn |
| Mar 31, 2023 | -26.73 Bn |
| Dec 31, 2022 | -38.15 Mn |
| Dec 31, 2022 | -38.15 Mn |
| Sep 30, 2022 | -42.11 Mn |
| Sep 30, 2022 | -42.11 Mn |